A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
Autor: | Malcolm M. Anderson, Michael C. Brodsky, Mark J. Kupersmith, Roy W. Beck, Constance W. Atwell, Barrett Katz, William T. Shults, Edward G. Buckley, Peter J. Savino, John L. Keltner, James J. Corbett, John A. McCrary, Patricia A. Cleary, John Guy, Georgia A. Chrousos, Neil R. Miller, David I. Kaufman, Jonathan D. Trobe, James Goodwin, Craig H. Smith, H. Stanley Thompson |
---|---|
Rok vydání: | 1992 |
Předmět: |
Chemotherapy
medicine.medical_specialty Visual acuity genetic structures business.industry medicine.drug_class medicine.medical_treatment General Medicine medicine.disease Placebo law.invention Surgery Randomized controlled trial Methylprednisolone law Prednisone Anesthesia medicine Corticosteroid Optic neuritis medicine.symptom business medicine.drug |
Zdroj: | New England Journal of Medicine. 326:581-588 |
ISSN: | 1533-4406 0028-4793 |
Popis: | Background and Methods. The use of corticosteroids to treat optic neuritis is controversial. At 15 clinical centers, we randomly assigned 457 patients with acute optic neuritis to receive oral prednisone (1 mg per kilogram of body weight per day) for 14 days; intravenous methylprednisolone (1 g per day) for 3 days, followed by oral prednisone (1 mg per kilogram per day) for 11 days; or oral placebo for 14 days. Visual function was assessed over a six-month follow-up period. Results. Visual function recovered faster in the group receiving intravenous methylprednisolone than in the placebo group; this was particularly true for the reversal of visual-field defects (P = 0.0001). Although the differences between the groups decreased with time, at six months the group that received intravenous methylprednisolone still had slightly better visual fields (P = 0.054), contrast sensitivity (P = 0.026), and color vision (P = 0.033) but not better visual acuity (P = 0.66). The outcome in the oral-prednisone group did ... |
Databáze: | OpenAIRE |
Externí odkaz: |